First Quadrant’s Enanta Pharmaceuticals ENTA Stock Holding History

First Quadrant’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,013	Closed	-$397K	–	525
2021 Q2	$397K	Hold	9,013	–	–	0.05%	270
2021 Q1	$445K	Hold	9,013	–	–	0.05%	270
2020 Q4	$379K	Buy	9,013 +7,708	+591%	+$339K	0.04%	283
2020 Q3	$60K	Sell	1,305 -1,072	-45%	-$51.9K	0.01%	475
2020 Q2	$119K	Buy	+2,377	New	+$123K	0.02%	512
2015 Q3	–	Sell	-6,700	Closed	-$301K	–	807
2015 Q2	$301K	Buy	+6,700	New	+$261K	0.01%	525

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Quadrant's ENTA Position: Q3 2021 in Review

First Quadrant sold out of Enanta Pharmaceuticals (ENTA) in Q3 2021, closing a stake of 9,013 shares — an estimated $397K sold.

First Quadrant first reported a position in ENTA in Q2 2015 and held it in 6 quarters. The position peaked at $445K in Q1 2021. 147 funds tracked by Wall St. Rank hold ENTA as of Q3 2021.

First Quadrant reported no remaining Enanta Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
First Quadrant sold 9,013 Enanta Pharmaceuticals shares in Q3 2021, an estimated $397K.
First Quadrant first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 6 quarters.
First Quadrant's Enanta Pharmaceuticals position peaked at $445K in Q1 2021.
147 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2021.

Based on First Quadrant's 13F filing for Q3 2021, filed 26 Oct 2021.